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ABSTRACT 
 
Adult mesenchymal progenitor cells have enormous potential for use in regenerative 
medicine. However, the true identity of the progenitors in vivo and their progeny has not been 
precisely defined. We hypothesize that cells expressing a smooth muscle α-actin promoter 
(αSMA) directed Cre transgene represent mesenchymal progenitors of adult bone tissue. By 
combining complementary colors in combination with transgenes activating at mature stages of 
the lineage we characterized the phenotype and confirmed the ability of isolated αSMA+ cells to 
progress from a progenitor to fully mature state. In vivo lineage tracing experiments using a new 
bone formation model confirmed the osteogenic phenotype of αSMA+ cells. In vitro analysis of 
the in vivo labeled SMA9+ cells supported their differentiation potential into mesenchymal 
lineages.  
Utilizing a fracture-healing model, αSMA+ cells served as a pool of fibrocartilage and 
skeletal progenitors. Confirmation of the transition of αSMA+ progenitor cells to mature 
osteoblasts during fracture healing was assessed by activation of bone specific Col2.3emd 
transgene. Our findings provide a novel in vivo identification of defined population of 
mesenchymal progenitor cells with active role in bone remodeling and regeneration. 
 
INTRODUCTION 
 
A full understanding of the recruitment of multipotent progenitors into the skeletal lineage and 
the factors influencing their differentiation is critical to the development of protocols to modulate 
bone regeneration and to the design of novel targets for pharmacological intervention. However, 
a major obstacle has been the unavailability of reproducible methods to identify these 
progenitors and to track their fate. Initial studies have characterized some phenotypic properties 
of these cells, but have not provided clear information on their origin. 
A perivascular niche has been implicated as a source of mesenchymal progenitors 1, 2. 
The human bone marrow derived stromal population expressing Stro-1 and CD146 exhibits the 
ability to form bone in vitro and in a heterotopic bone formation assay in vivo. This population of 
cells is localized in the proximity of endothelial cells and was positive for αSMA expression 3. 
Sacchetti et al. defined a population of osteoprogenitors as CD146+ subendothelial cells in bone 
marrow suggesting that perivascular cells exhibit potential for self-renewal and differentiation 
supportive of hematopoiesis 4. Crisan et al observed perivascular cells in various organs with 
the ability to differentiate into multiple mesenchymal lineages 5.  
Recently, we described a population of cells expressing smooth muscle actin alpha 
(αSMA) that have osteogenic potential 6. The αSMAGFP cells are located in perivascular 
niches, periosteum and sutures, regions that contain osteoprogenitor cells. Moreover, 
αSMAGFP+ cells derived from primary BMSCs and ADSCs of transgenic mice exhibit 
osteogenic and adipogenic potential 6. A high proportion of αSMAGFP+ cells express the stem 
cell markers; stem cell antigen 1 (Sca1) and CD90 but lack expression of the CD117 (c-kit) or 
CD11b 7-9.  
A detailed characterization of progenitor cells requires methods to isolate the cells and 
trace their transition into different phenotypes. The use of cell surface markers is limited by the 
fact that progenitor cells may loose markers as they differentiate.  
We have generated αSMACreERT2 transgenic mice, which provide the system in which 
the fate of the progenitors could be traced. We propose to examine the ability of αSMACreERT2 
expressing cells as mesenchymal progenitors during bone formation and repair and to 
determine whether these progenitor cells become committed to specific lineages.   The 
combinatorial approach of using Cre recombinase fused to a modified estrogen receptor ligand 
binding domains (ERT2) permits the temporal induction by delivery of a tamoxifen and tissue 
specificity by directing the Cre expression with a lineage specific promoter 10. When crossed 
with Ai9 reporter mice, recombination can be detected by expression of red fluorescence 
(TdTomato) 11. This system allows for the spatial and temporal activation of Cre labeling and 
identifying the labeled population, and tracing the lineage progenies of the labeled cells for 
prolonged period after the tamoxifen treatment has been terminated.  Here we utilized the visual 
markers for transgene expression and the Cre/loxP recombination system for lineage tracing 
using a fragment of the αSMA promoter 6. We have utilized murine models harboring real-time 
visual transgenes in combination with cell surface markers and Cre/loxP technology as a 
powerful way of characterizing mesenchymal progenitors.  
These approaches have defined a mesenchymal progenitor cell in vivo that actively 
participates in the physiological process of bone remodeling and during the regenerative 
processes of fracture healing.  
 
 
 
MATERIALS AND METHODS 
Generation of transgenic mice and animal studies 
Detailed description of generation of αSMACreERT2 mice is outlined in the Suppl. Methods. 
The generation and characterization of αSMAGFP, Col2.3cyan, Col2a1cyan and Col2.3emd 
mice has been published 6, 12, 13.  Mice transgenic for AP2cyan and αSMAcherry have been 
recently developed 14. The αSMACreERT2/Ai9 dual transgenic mice mice (term SMA9 will be 
used) were generated by breeding αSMACreERT2 male mice and Ai9 female mice that were 
obtained from Jackson labs (stock # 007909). The Ai9 mice harbor a targeted mutation of the 
Gt(ROSA)26Sor locus with a loxP-flanked STOP cassette preventing transcription of a CAG 
promoter-driven red fluorescent protein variant (tdTomato). For in vivo lineage tracing studies 4-
5 weeks old mice were treated with tamoxifen at the dose of 75 µg/g of weight. Mice were 
treated twice in the interval of 24 hours and sacrificed 2 days or 17 days later. The SMA9 
untreated mice and αSMACreERT2 negative/Ai9 treated mice were evaluated as controls.  
 
In vitro studies 
Primary BMSC were prepared as previously described 15. Following cell separation using 
fluorescent activated cell sorting (FACS), cells were plated at the density of 10,000 cells/cm2 in 
24 well plates. Cells were induced to osteogenesis using DMEM/10%FCS medium 
supplemented with 50µg/ml ascorbic acid and 8mM ß-glycerol phosphate for two weeks, while 
adipogenesis was induced using media supplemented with1 µM Insulin and 0.5 µM 
rosiglitasone for 7 days. To evaluate chondrogenesis sorted SMA9+ and SMA9- population were 
seeded as a 20 µl spot containing 5x104 cells. After 2 hr, αMEM/10%FCS was added and cells 
were, for 7 days, placed under chondrogenic induction (serum free media supplemented with 50 
µg/ml ascorbic acid, 10 ng/ml TGFß3, 100 nM dexamethasone, 40 µg/ml L-proline, sodium 
pyruvate, ITS+ 1 and cultured in 5% oxygen). Methods evaluating osteogenesis, adipogenesis 
and chondrogenesis in vitro are presented within Suppl. Methods section.   
 
Histology 
Bone samples for histology were fixed for 3-5 days in 10% formalin (Sigma) and decalcified in 
15%EDTA for 4-7 days depending on the age of animal, placed in sucrose overnight and 
embedded in cryomedium (Thermo scientific). Soft tissues were fixed overnight and after 24 
hours in sucrose they were embedded and sectioned. Sections of 5µm were obtained using a 
Leica cryostat and tape transfer system (Japanese tape). Images were obtained by appropriate 
filter cubes optimized for GFP variants (Chroma) using a Zeiss Observer.Z1 microscope. 
Images were obtained in grey scale, pseudocolored and composite images assembled. To 
obtain a full size image of bone, images were scanned at high power and then stitched into a 
composite. Following fluorescent imaging sections were stained with hematoxyllin and imaged.  
 
Flow cytometry 
FACS analysis and cell sorting of αSMAcherry+, and αSMACreERT2/Ai9 cells were performed 
using a BD FACSAria I (BD Biosciences. San Jose, CA, USA) equipped with five lasers and 18 
fluorescence detectors. Flushed bone marrow cells, and enzymatically digested (collagenase 
0.2%, hyalouronidase 0.2% in 0.25 trypsin) periosteal layer cells were used. Erythrocytes were 
lysed by hypotonic shock. Sorting gates were defined using cells from non-transgenic and 
transgenic mice bearing individual transgenes. Single cell suspensions were prepared in 
staining medium (2% FCS/HBSS/HEPES). For phenotype characterization we used 
commercially available antibodies (Ab) as described in detail in Supp. Material. 
RESULTS 
αSMA+ cells exhibit characteristics of mesenchymal progenitor cells. 
To evaluate the localization of cells expressing αSMA we analyzed mice expressing cherry FP 
under the control of αSMA promoter. In bone marrow and periosteum we observed 
αSMAcherry+ cells in association with microvasculature. In addition to perivascular location, we 
observed αSMAcherry+ fibroblastic shaped cells in periosteum (figure 1a-d, see suppl. figure 1a 
for whole bone section). FACS analyses of freshly isolated cells indicated that the αSMA 
transgene is active in 0.02-0.03% of cells in bone marrow and in around 1% of scraped cells 
from periosteum (figure 1e-h). The identified population in bone marrow can be expanded in 
vitro by day 7 (figure 1i). To assess the ability to differentiate into osteogenic lineage 
αSMAcherry+ and αSMAcherry- population were sorted from a dual transgenic mouse harboring 
the osteoblast specific reporter, Col2.3cyan (figure 1j). These cells were then replated and 
grown under lineage inductive conditions. We confirmed that αSMAcherry+ cells differentiated 
into mature osteoblasts and expressed Col2.3cyan on day 7 (figure 1l) and day 14 (figure 1n). In 
contrast, αSMAcherry- cells did not generate colonies or express osteogenic marker (figure 1k, 
m). The profile of cells derived from αSMAcherry+ population was confirmed by alkaline 
phosphatase expression, mineralization and the expression of bone sialoprotein and osteocalcin 
(figure 1o-p). Similar experiments driving sorted cells into adipogenesis and chondrogenesis, 
showed that the αSMAcherry+ population has the ability to differentiate into mature adipocytes 
and chondrocytes. Adipogenesis was detected by staining for oil-red-o and expression of 
AP2cyan and mRNA for adipsin and adiponectin (suppl. figure 1b), while chondrogenic 
differentiation was analyzed by alcian blue staining and aggrecan mRNA expression (data not 
shown).  
 
 
Lineage tracing identifies progenitor population during normal skeletal remodeling. 
In order to determine whether αSMA promoter can identify cells with progenitor activity 
in vivo, we generated αSMACreERT2 transgenic mice and we characterized its expression by 
crossing it with the Ai9 reporter transgenic line to generate αSMACreERT2/Ai9 (SMA9) mice 
(figure 2a). In these mice the expression of the Cre molecule is activated under the control of 
the αSMA promoter upon treatment with tamoxifen. This allows the tracking of developmental 
progression of αSMA expressing cells by activating the expression of the tdTomato visual 
reporter through Cre-mediated recombination. Mice were treated with tamoxifen and analyzed 
at days 2 and 17 after treatment (figure 2b-d). Two days after treatment SMA9+ cells defined a 
small population of cells present in primary spongiosa (figure 2c) or within the periosteum 
(suppl. figure 2a). No cells expressing SMA9 reporter were detected within the bone matrix 
(figure 2c). Interestingly, 17 days after the tamoxifen activation we found numerous osteoblast 
and osteocytes labeled by the transgene. Image analysis revealed that 23.4±3.2% of bone 
matrix embedded cells were SMA9+ at this time point. These observations confirm the ability 
of the αSMA directed Cre to target osteoprogenitor cells in vivo (figure 2d). We have confirmed 
that the αSMACreERT2 activity was ligand dependent in adult bone and other tissues. In the 
absence of tamoxifen we did not detect leaky expression of tdTomato in bone tissue (suppl. 
figure 2a). However, a significant leak of the Cre expression was observed in tissues with a 
strong endogenous activity of αSMA gene like bladder, and aorta (suppl. figure 2b). 
To further evaluate the distribution of labeled cells generated after αSMACre activation, 
we analyzed primary cultures at days 3 and 7 by flow cytometry. We did not detect expression 
of tdTomato in cells derived from αSMACrenegative/Ai9/Tx treated mice (figure 2f, i) at days 3 or 7, 
or in cells derived from SMA9 untreated mice on day 3 in culture (figure 2g). However, an 
appreciable activation of Cre-directed recombination was observed in SMA9 treated mice by 
day 3 (1-2%) and by day 7 (23-27%) (figure 2h, k). A small proportion of cells showed a 
spontaneous Cre activation in primary cultures derived from SMA9 non-treated mice (figure 2j) 
by day 7. The spontaneous activation of SMACreERT2 transgene in vitro is due the increase of 
SMA promoter activity and the presence of number of serum response elements in the proximal 
sequence of SMA promoter 16.  
In addition, primary cultures derived from untreated SMA9 mice, subsequently treated in 
vitro by 4-OH tamoxifen, showed expression of tdTomato in a similar proportion of cells (suppl. 
figure 2c). This confirms our in vivo observation that we are selectively targeting a progenitor 
population that exhibits ability to differentiate into mature osteoblasts in vivo and in vitro.  
 
Differentiation potential of SMA9 labeled progenitor population. 
To test the progenitor ability of the in vivo labeled SMA9 cells we established primary 
cultures from SMA9 mice that were treated with tamoxifen for 2 days (figure 2b). Following one 
day in culture, individual SMA9+ cells were evident, and over time they expanded in number 
forming colonies during the first 7 days of culture (figure 2e). After induction of osteogenic 
differentiation SMA9+ cells formed multilayered nodules with the ability to mineralize. To 
substantiate these results, we have utilized primary BMSC cultures derived from 
SMA9/AP2Cyan and SMA9/Col2.3emd mice treated with tamoxifen. Two days after treatment, 
cultures were established and after reaching confluence were induced to adipogenesis and 
osteogenesis. We have observed numerous SMA+ cells differentiating into adipocytes or 
osteoblasts as detected by the expression of AP2cyan (figure 3b-c), or Col2.3emd respectively 
(figure 3e-f). To evaluate chondrogenic differentiation SMA9 mice were utilized, and cells we 
sorted into SMA9+ and SMA9- populations on day 7 of culture. Following differentiation we 
observed the formation of alcian blue positive nodules in the cultures derived from SMA9+ cells 
(figure 3i). Cultures of unsorted or SMA9- cells did not form alcian blue positive nodules (figure 
3g-h) even after prolong period in culture. The SMA9+ population shows also enhanced mRNA 
expression of chondrogenic markers Col2a1 and aggrecan (data not shown).  
Our data clearly shows that the SMA9 transgenic constructs provided a bona-fide 
identification of mesenchymal progenitor cells and should allow further characterization of this 
population of cells using markers currently proposed as signature molecules for stem cells. 
 
Multiple mesenchymal stem cell markers are present on SMA9 labeled cells. 
In addition to the histological assessment, we followed the percentage of SMA9+ labeled 
cells in vivo at days 2 and 17 after tamoxifen treatment by flow cytometry. We found an increase 
in the percentage of cells expressing tdTomato reporter in the bone marrow up to 0.3% at day 
17, compared to the 0.02% observed for the expression of αSMAcherry in basal conditions 
(figure 4a). In contrast, the percentage of SMA9+ cells isolated from the periosteal layer was 
approximately 1% and was maintained along a time-course evaluation (figure 4b, and suppl. 
figure 4a). We used multicolor FACS analysis to test if the reporter signal correlated to markers 
of the hematopoietic lineage. To evaluate hematopoietic markers we used a combination of 
antibodies for CD45, Ter119 and CD11b. Interestingly, most of the SMA9+ cells present in the 
bone marrow cells expressed markers characteristic of hematopoietic lineage, whereas the 
majority of the SMA9+ periosteal cells were (CD45/Ter119/CD11b)- (figures 4a and 4b). Among 
the (CD45/Ter119/CD11b)- SMA9+ bone marrow population, approximately one third of the cells 
were CD45+Ter119-CD11b- (not shown). We also analyzed gated SMA9+ cells for the co-
expression of cell surface markers associated with mesenchymal progenitor cells and found that 
SMA9+ population maintained a stable expression pattern when analyzed at day 2 and 17 after 
transgene induction (figures 4c-d, suppl figure 4b). Bone marrow cells that are tdTomato+ and 
(CD45/Ter119/CD11b)- were mostly negative for the included mesenchymal lineage markers, 
except for CD31 that was weakly expressed on approximately 5% cells on day 17 (figure 4c). 
Percentages of hematopoietic marker positive SMA9+ bone marrow cells expressing 
mesenchymal markers vary between 10-30%, with CD31 being the most prominently expressed 
(figure 4c). This percentage of CD31+ cells was much lower (<0.1%) in αSMAcherry labeled 
cells (data not shown), indicating induction of CD31 expression after tamoxifen activation of Cre 
mediated recombination. 
The periosteal SMA9+ cells had a different phenotype, mostly lacking expression of 
hematopoietic markers but strongly expressing Sca1 and CD90 on approximately 20% of the 
population and weakly expressing CD51 on approximately a third of the population at day 2 
after transgene induction (figure 4d, and suppl. figure 4b).  
The in vitro system allows for the expansion of the progenitor population, but comes with 
a number of variables including serum composition and selective expansion of the adherent 
population of cells. Therefore, we evaluated the expression of cell surface markers that are 
used to characterize mesenchymal progenitor cells in vitro. Following our in vivo indication that 
majority of SMA9+ bone marrow cells are positive for the hematopoietic lineage markers we 
have evaluated the expression of SMA9+ cells for the presence of Sca1, CD51, CD140b, CD31 
and CD146 in the context of CD45/Ter119 expression. During the first 3 days in culture SMA9+ 
cells lose the expression of CD45/Ter119, which is present in about 2% of cells on day 3 and 
6% on day 7 (suppl. figure 4). The expression of Sca1 and CD51 was observed by 30-40% of 
cells on day 3 and increased up to 50-60% of cells on day 7, while CD140b was expressed at 
much lower levels (suppl. figure 4). We did not observe the expression of CD31 or CD146 in 
primary stromal cell cultures at either time point (not shown). 
 
Origin of mesenhymal lineages during fracture repair. 
To determine whether SMA9 expressing cells participate in the regenerative processes 
including generation of chondrocytes and osteoblasts we utilized a tibia fracture model. The 
experimental design included treatment with tamoxifen, on the day before and on the day of 
fracture. The aim was to label the population of αSMA expressing cells and then trace their 
progeny during the fracture healing process.  
During the first week following injury expansion of SMA9+ cells within bone marrow and 
periosteum was observed (figure 5a). Interestingly, we detected the presence of SMA9+ 
expressing cells in newly formed chondrogenic areas of the fracture callus, and areas of the 
new bone formation (figure 5b). We correlated the presence of these osteoblasts with the 
dynamic formation of new bone through injection of calcein dye one day before sacrificing the 
mice. The osteoblasts derived from SMA9+ progenitor cells showed intense deposition of new 
bone, indicated by the correlation between calcein label (green) and tdTomato (red) positive 
cells (figure 5b). These results clearly indicated that the labeled populations present within the 
periosteum and bone marrow actively participate in all the aspects of fibrochondral ossification.  
To track the population of SMA9+ cells into mature osteoblast we bred a bone specific 
transgene into the SMA9 mice. The expression of SMA9+ cells (red-tdTomato) co-localized to 
Col2.3emd expressing mature osteoblasts (green, SMA9/2.3GFP) (figure 5d-g). This finding is 
direct evidence for terminal differentiation of SMA9+ cells into mature osteoblasts in vivo. A 
representative image of a control fractured bone from SMA9 mouse not injected with tamoxifen 
is shown in figure 5c. No major leak of spontaneous Cre expression was detected following 
fracture of SMA9 untreated mice. 
The majority of the cartilaginous callus cells were SMA9+ indicating differentiation into 
chondrocytes (figure 5b and 5f-g arrowheads). In addition to the morphological characterization 
of chondrocytes we have introduced a chondrocyte lineage directed reporter (Cyan) using a 
Col2a1 transgene. One week following bone fracture in SMA9/Col2a1 mice we have observed a 
population of dual SMA9/Col2a1Cyan expressing cells indicating that the SMA9+ population 
labeled prior to fracture healing can gave rise to Col2a1 expressing cells (suppl. figure 5).  
To define the contribution of the SMA9 mesenchymal progenitor cells to newly formed 
bone following completion of the fracture healing process we assessed the 6-week post-fracture 
time point. Mice transgenic for SMA9/Col2.3emd were fractured and cell-lineage traced 
following callus remodeling (figure 6). The contribution of the SMA9+ cell was detected by 
persistence of the dual SMA9+/Col2.3emd labeled cells (osteoblasts and osteocytes) within the 
new bone 6 weeks into the reparation process (figure 6a-d, arrows indicate numerous dual 
SMA9/Col2.3emd expressing osteoblasts and osteocytes). 
 
DISCUSSION 
Skeletal stem cell, as a term, has been proposed for the population of mesechymal 
progenitor cells residing within bone marrow compartment 17, 18. The most accepted markers to 
define human MSCs are Stro-1, recognizing a milieu of cell surface glycoproteins, and 
MCAM/CD146, a marker that has been associated with subendothelial perivascular cells 5, 19. 
Recently, the expression of nestin driven reporters has been associated with a population of 
bone marrow cells that can differentiate into mesenchymal lineages 20. Although useful to isolate 
cells from bone marrow and primary cell cultures, these markers do not allow for lineage tracing 
of the progeny of the mesenchymal stem cell since they are only transiently expressed at 
certain stages of differentiation.  
The origin of the mature osteoblast remains elusive. We hypothesize that the αSMA 
transgene expression could be a marker for a cell that can give rise not only to osteoblasts but 
also to other mesenchymal lineage cells. We have addressed this by using an αSMACreERT2 
transgene aiming to confirm the progenitor potential of αSMA expressing perivascular cell in 
vivo. We were able to trace the progeny of the perivascular cell into the mature osteoblasts and 
osteocytes, the final stage of skeletal lineage differentiation. These data indicate that during the 
process of bone formation and remodeling the αSMA transgene identifies skeletal stem cells. 
These observations prompted us to define the surface markers in the cells identified by 
αSMAcherry as well as SMA9 expression. A high proportion of αSMAcherry+ and SMA9+ cells, 
expressed markers associated with hematopoietic cells including CD45. The exclusiveness of 
CD45 as pan-hematopoietic marker has been recently challenged, indicating that mesenchymal 
progenitor cells can express markers currently used to define hematopoietic lineage 21, 22.  
Skeletal stem cell interactions with endothelial cells are critical for early invasion of vasculature 
during embryonic development and for the translocation of skeletal stem cells into the newly 
formed bone marrow cavity 23. However, recent literature has proposed alternative definitions for 
the identity of the mesechymal progenitor cells regarding their expression of endothelial cell 
markers. Medici et al. described cells with endothelial phenotype exhibiting the ability to 
differentiate into mesenchymal cell lineages 24. Other report, using a co-culture model of human 
embryonic stem cells with mouse OP9 stromal cells, defined a common precursor for 
endothelial and mesenchymal cell lineages, termed mesenchymoangioblast 25. These studies 
cannot be strictly compared as they are derived from different experimental models. However, 
they provide evidence for a close relationship between mesenchymal and endothelial lineage 
cells. In our study we have observed the expression of αSMAcherry in proximity to endothelial 
cells, while very few or none αSMAcherry+ co-expressed CD31 marker. Nevertheless, when the 
progeny of the SMA9 cells was traced in vivo we observed a weak co-expression of CD31 in 
approximately 5% of the (CD45/Ter119/CD11b)-, SMA9+ cells. The proportion of CD31+/SMA9+ 
cells represents about 30% of the cells positive for markers of hematopoietic lineage. These 
findings suggest the possibility that SMA9 labeled progenitor cells, located in the perivascular 
region, have the ability to mature into cells with an endothelial phenotype. In addition, within 
SMA9+ bone marrow population that are positive for hematopoietic markers we observed 
approximately 20% of CD146+/SMA9+ cells, while there were very few or none CD146 
expressing cells among periosteal layer or in vitro expanded SMA9+ cells. Future studies have 
to be aimed to define these populations using a combination of approaches and multiple 
markers for both mesenchymal and endothelial lineages.  
To test functionally the proposed hypothesis, the osteogenic potential of SMA9 labeled 
cells was tested in a bone injury model. Our data indicate that the majority of the callus cells 
following fracture, including chondrocytes and osteoblasts, are derived from SMA9 expressing 
cells. Interestingly, the expansion of the SMA9+ cells occurred both in periosteum and within 
bone marrow, and resulted into SMA9+ cells with mature bone cell phenotypes contributing to 
the fracture healing process. Our work provides direct in vitro and in vivo evidence that the use 
of SMA9 labeled cells should allow the selective identification and isolation of progenitor cells 
that participate actively in the fracture healing process. Moreover, our studies on SMA9 labeled 
cells support the conclusion that αSMA expression marks genuine mesenchymal progenitors 
with multilineage properties in vivo and in vitro. By utilizing SMA9 labeled cells in combination 
with visual markers of mature lineages, we could identify pathways important for lineage 
determination that could provide therapeutic targets for the enhancement of the regenerative 
processes. 
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Figure Legends: 
 
Figure 1. αSMAcherry expressing cells display osteoprogenitor potential. 
(a-d) The expression of αSMAcherry is localized to the perivascular area of capillaries within 
periosteum and muscle (a-b, see arrows) and bone marrow (c-d, arrowheads).  
(e-h) FACS analysis for αSMAcherry expression in samples derived from enzymatically 
digested periosteum (e-f) or whole bone marrow from transgenic (g-h) or non-transgenic mice 
(e, g). Proportion of αSMAcherry expressing cells is indicated in the right lower corner of the 
plots (four αSMAcherry mice were analyzed individually and the representative values are 
shown). 
(i-j) Primary BMSC derived from αSMAcherry/Col2.3cyan mice were grown for 7 days and 
imaged under transmitted (left), red (middle) and blue (right) epifluorescence. αSMAcherry 
expression was present in fibroblastic shaped cells while no expression of Col2.3cyan was 
detected (i). αSMAcherry-expressing cells (j, left panel, 23% of cells) were collected by FACS 
sorting; reanalysis of the sorted population purity is shown for αSMAcherry– and αSMAcherry+ 
cells (j, middle and left panels). 
(k-l) Following sorting, cells were replated and induced to osteogenesis and FACS analyzed on 
day 7. αSMAcherry– cells did not activate Col2.3cyan (k) while α-SMAcherry+ showed 
differentiation into Col2.3cyan+ cells (l). Col2.3cyan was detected at day 14 in population of 
differentiated α-SMAcherry+ cells (n), with no expression in α-SMAcherry- population (m).  
(o-p) Alkaline phosphatase expression and mineralization (arrows) was detected in 
αSMAcherry+ cells in contrast to αSMAcherry- cells (o). Real-time PCR shows increased 
expression of BSP and OC after osteogenic induction of α-SMAcherry+ cells (p). 
  
Figure 2. Cell lineage tracing experiments following in vivo transgene activation. 
(a) The αSMACreERT2 transgenic construct harboring sequence of αSMA regulatory elements. 
These mice were crossed with a Cre recombinase reporter strain Ai9. In dual expressing SMA9 
mice tamoxifen-induced Cre recombinase activates expression of tdTomato.  
(b) Diagram of experimental approach for the cell lineage tracing experiments. Mice were 
sacrificed on day 2 and 17 following tamoxifen treatment and evaluated by histological analysis. 
Primary BMSC were established from mice treated with tamoxifen and sacrificed on day 2 after 
treatment. 
(c-d) Histological analysis of SMA9 recombination identifies SMA9+ cells within the trabecular 
area (TR) but not inside the bone matrix (arrowheads). No expression is observed in the growth 
plate (GP) chondrocytes. Seventeen days after the initial evaluation (day 17) we could track the 
SMA9+ cells to osteoblasts lining trabecular bone (d, arrowheads) and ostecytes embedded 
within bone (arrows). Shown are representative images of 6-7 mice per group analyzed at each 
time point. 
(e) Epifluorescent imaging of primary BMSC derived from SMA9 mice treated with tamoxifen. 
Once labeled in vivo, SMA9+ cells expanded during the first week in culture, formed nodules 
and underwent mineralization (see arrows).  
(f-k) FACS analysis of primary BMSC (days 3 (f-h) and 7 (j-k)) derived from SMA9+ labeled cells 
following tamoxifen injection in vivo. αSMACreERT2negative/Ai9 mice treated with tamoxifen (f, i), 
and SMA9 mice without treatment (g, j) served as a controls. In vivo treatment labeled SMA9+ 
cells account for about 1% of cells on day 3 and close to 25% on day 7 of the culture (h, k). 
 
Figure 3. Multilineage potential of SMA9 progenitor cells. 
(a-f) Primary BMSC were established from SMA9/Col2.3emd and SMA9/AP2cyan mice treated 
with tamoxifen for 2 days. Cells were then grown to confluence and induced to osteogenic or 
adipogenic differentiation respectively. Osteogenic differentiation was confirmed by dual 
expression of red-labeled SMA9 (b), and green-labeled Col2.3emd osteoblast lineage cells (c), 
(phase is shown in a). Adipogenic differentiation was confirmed by dual expression of red-
labeled SMA9 (e), and blue labeled AP2cyan adipocytes (f), (phase is shown in d).  
(g-i) To evaluate chondrogenesis cells derived from SMA9 mice cells were cultured for 7 days, 
and then sorted into SMA9+ and SMA9- population and placed under chondrogenic conditions 
for 9 days. Formation of chondrogenic nodules was detected using alcian blue staining in sorted 
SMA9+ cells (i), in contrast to SMA9- (h) and unsorted BMSC (g). 
 
Figure 4. Distinct phenotype of αSMACre labeled cells from the bone marrow 
compartment and periosteum.  
(a-b) Left-side graphs present FACS analysis of the percentage of αSMAcherry and SMA9 
labeled cells (SMA9+) (2 and 17 days following tamoxifen injection) within the bone marrow (a) 
and among periosteal cells (b). Right-side graphs present relative proportion of 
(CD45/Ter119/Cd11b)+ vs. (CD45/Ter119/Cd11b)– populations among αSMAcherry and SMA9+ 
cells. Each group included 2-3 independent samples pooled from the respective tissue of 2-3 
mice. To determine the percentage of SMA9+ cells at least 2.5x106 cells for bone marrow and 
0.25x106 for periosteal cells were analyzed. Gates were set in accord to the control populations 
from tamoxifen injected αSMACrenegative/Ai9 mice. Mice without tamoxifen treatment, carrying 
the transgene SMA9 served for the Cre-leakage control and contained a percentage of 
tdTomato+ cells comparable to the control mice (not shown).  
(c-d). Phenotyping of SMA9+ cells 2 and 17 days following transgene activation. Graphs 
represent the percentage of the population expressing respective mesenchymal cell markers 
within (CD45/Ter119/Cd11b)+ vs. (CD45/Ter119/Cd11b)– compartments of the SMA9+ cells. 
FACS analysis was performed by gating SMA9+ cells and plotting them using markers for 
hematopoietic lineage (CD45/Ter119/CD11b) vs. respective proposed mesenchymal lineage 
marker (Sca1, CD90, CD31, CD51 Cd140b, CD146 or CD106) within the bone marrow (c) and 
periosteal cell populations (d). Values represent mean±SD of the percentage of respective 
population from 2-3 independent samples pooled from 2-3 mice. 
  
Figure 5. Mesenchymal progenitor cell lineage tracing during fracture healing. 
(a-b) Osteogenesis during fracture healing is examined at one and two weeks following fracture. 
The expression of SMA9 is detected in the periosteal layer of cells (a, arrowheads point to the 
expanded SMA9+ cells within periosteum) located in the proximity to the fracture site (indicated 
by perforated lines; CB - cortical bone, BM - bone marrow). One week after fracture SMA9+ cells 
comprise most of the periosteal layer around fracture site. Bone marrow is also filled with 
SMA9+ cells. Two weeks after the fracture new cartilaginous callus formation is observed (b, 
arrowheads), while new bone formation is detected by deposition of calcein (green). Osteogenic 
lineage cells labeled by the SMA9 reporter (red, tdTomato+) persist in proximity to the large and 
intermingled calcein labeled areas within the callus. 
(c) Two week post fracture callus of a SMA9 control mouse (tamoxifen non treated) showing 
extensive calcein labeling but minimal reporter leakage. 
(d-e) The same experimental design was completed in a SMA9/Col2.3emd model. The 
expression of SMA9+ cells (d, red) co-localizes with the expression of osteoblast specific marker 
Col2.3emd (e, green), as indicated by the presence of yellow color (overlay image, f). To 
provide better orientation within the area of callus same sections were stained by hematoxylin 
(g).  

Figure 6. SMA9+ cells contribute to new bone formation following fracture healing. 
(a-c) Osteogenesis following fracture healing and callus remodeling is examined at 6 weeks 
following fractures. The expression of SMA9 (a), Col2.3emd (b) and the overlayed image was 
evaluated for the presence of the dual expressing mature osteoblast lineage cells (c). 
Hematoxylin staining of the same section has been completed following epifluorescence 
imaging (d). The expression of SMA9 is detected in the periosteal layer of cells (a, c, see 
arrowheads point to the expanded SMA9+ cells within periosteum), within the osteoblast layer 
(c, indicated by arrows), among osteocytes and within the muscle. High magnification (20x) 
clearly identifies the presence of numerous cells that express both SMA9 and Col2.3emd 
markers (c, see yellow cells on the bone surface and within the bone matrix). (20x), BM - bone 
marrow, and CB - cortical bone. For this experiment unilateral fractures were performed in 3 
mice. 
 
 
  
